Keith Kohout, DO
Neurology · Des Moines, IANPI 1982043782
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. EMD Serono, Inc. accounts for 66.4% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2019 at $17,857 and has fallen 95.7% since, to $771 in 2025. Among neurology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $154.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$24K
- Biogen$7K
- Genentech, Inc.$850
- Teva Pharmaceuticals USA, Inc.$703
- TG Therapeutics, Inc.$459
- AbbVie$432
- plus $2K from 31 others
What the payments were for
- Consulting fees$6,11417%
- Speaking & faculty fees$19,16053%
- Travel & lodging$5,39315%
- Food & beverage$4,81313%
- Education$5932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 45 | $23,967 |
| Biogen | 38 | $7,262 |
| Genentech, Inc. | 1 | $850 |
| Teva Pharmaceuticals USA, Inc. | 28 | $703 |
| TG Therapeutics, Inc. | 20 | $459 |
| AbbVie(2 entities) | 16 | $432 |
| Medtronic | 6 | $428 |
| Novartis | 11 | $265 |
| UCB, Inc. | 7 | $132 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Amgen | 7 | $125 |
| Lilly USA, LLC | 3 | $116 |
| Vanda Pharmaceuticals Inc. | 1 | $105 |
| Johnson & Johnson | 1 | $99 |
| Pfizer | 5 | $97 |
| Genentech USA, Inc. | 2 | $97 |
| AstraZeneca(2 entities) | 3 | $93 |
| Adamas Pharmaceuticals, Inc. | 5 | $83 |
| Livanova USA, Inc. | 3 | $73 |
| Acorda Therapeutics, Inc | 4 | $70 |
| Eisai Inc. | 3 | $60 |
| Argenx US, Inc. | 2 | $53 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| Merz North America, Inc. | 2 | $36 |
| Tanabe Pharma America, Inc. | 2 | $33 |
| Bristol Myers Squibb | 2 | $32 |
| Sanofi | 2 | $32 |
| CSL Behring | 1 | $32 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| GE HealthCare | 1 | $29 |
| Promius Pharma LLC | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| MDD US Operations, LLC | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,073 in reported general payments places this provider in the 90th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AubagioTeriflunomide | 12 | $110,352 |
| EpidiolexCannabidiol (Cbd) | 13 | $67,570 |
| BriviactBrivaracetam | 12 | $39,322 |
| RytaryCarbidopa/Levodopa | 49 | $38,525 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 574 | $19,938 |
| Nurtec OdtRimegepant Sulfate | 13 | $16,576 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $13,663 |
| Lacosamide | 136 | $9,145 |
| Levetiracetam | 178 | $6,850 |
| Acetazolamide | 17 | $2,959 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 115 | $2,447 |
| Zonisamide | 71 | $2,253 |
| Propranolol Hcl | 120 | $2,128 |
| Felbamate | 14 | $2,055 |
| Mycophenolate Mofetil | 14 | $1,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $32 | $110,35212 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil | $31 | $40,45963 claims |
| UCB, Inc.Briviact | $132 | $39,32212 claims |
| PfizerNurtec Odt | $97 | $16,57613 claims |
| Upsher-smith Laboratories LLCTopiramate | $15 | $55964 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 132 neurology providers in Iowa.
Other neurology in Des Moines
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Mark PuricelliDes Moines$45K
- Erik ArnesonDes Moines$10K
- John WrightDes Moines$9K
- Lynn StruckDes Moines$6K
- Irving WolfeDes Moines$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.